International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 1 , Pages 12-14 , 1 September 2008

Balancing on a Knife's Edge: Evidence-Based Medicine and the Marketing of Health Technology

References 

  1. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: What it is and what it isn't. BMJ. 1996;312:71–72
  2. Bentzen SM. Towards evidence based radiation oncology: Improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. Radiother Oncol. 1998;46:5–18
  3. Bentzen SM. A user's guide to evidence-based oncology. Eur J Cancer. 2003;S6(Suppl. 1):77–91
  4. Soares HP, Kumar A, Daniels S, et al. Evaluation of new treatments in radiation oncology: Are they better than standard treatments?. JAMA. 2005;293:970–978
  5. Meropol NJ. A renewed call for equipoise. J Clin Oncol. 2007;25:3392–3394
  6. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–1260
  7. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027–1032
  8. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol. 2005;23:5960–5972
  9. Machtay M, Pajak TF, Suntharalingam M, et al. Radiotherapy with or without erythropoietin for anemic patients with head-and-neck cancer: A randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys. 2007;69:1008–1017
  10. Overgaard J, Hoff C, Hansen HS, et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)—The Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer Suppl. 2007;6:7
  11. Stone GW, Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: The TAXUS V ISR randomized trial. JAMA. 2006;295:1253–1263
  12. Saunders MI, Dische S, Grosch EJ, et al. Experience with CHART. Int J Radiat Oncol Biol Phys. 1991;21:871–878
  13. Dische S, Saunders MI, Barrett A, et al. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44:123–136
  14. Bentzen SM, Saunders MI, Dische S, et al. Radiotherapy-related early morbidity in head and neck cancer: Quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol. 2001;60:123–135
  15. Accuray. CyberKnife® system shows momentum as treatment option for prostate cancer. Press release, September 25, 2007. Internet Website. Available from: http://www.accuray.com/PressReleases.aspx?release=660. Accessed January 15, 2008.
  16. Bentzen SM. Randomized controlled trials in health technology assessment: Overkill or overdue?. Radiother Oncol. 2008;86:142–147
  17. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  18. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50:1021–1031
  19. Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: What is it, really?. Radiother Oncol. 2005;76:1–3
  20. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23:6132–6138
  21. Miles EF, Robert LW. Hypofractionation for prostate cancer: A critical review. Semin Radiat Oncol. 2008;18:41–47
  22. Ritter MA, Forman JD, Kupelian PA, et al. A phase I/II trial of dose-per-fraction escalation for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;69:S174
  23. Hannoun-Levi JM, Benezery K, Bondiau PY, et al. [Robotic radiotherapy for prostate cancer with CyberKnife]. Cancer Radiother. 2007;11:476–482
  24. Pawlicki T, Cotrutz C, King C. Prostate cancer therapy with stereotactic body radiation therapy. Front Radiat Ther Oncol. 2007;40:395–406
  25. Pawlicki T, Kim GY, Hsu A, et al. Investigation of LINAC-based image-guided hypofractionated prostate radiotherapy. Med Dosim. 2007;32:71–79
  26. De Crevoisier R, Lagrange JL, Messai T, et al. [Prostate localization systems for prostate radiotherapy]. Cancer Radiother. 2006;10:394–401
  27. King CR, Lehmann J, Adler JR, et al. CyberKnife radiotherapy for localized prostate cancer: Rationale and technical feasibility. Technol Cancer Res Treat. 2003;2:25–30
  28. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol. 2007;25:4096–4103
  29. Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol. 2004;22:19–22
  30. Bentzen SM, Vaeth M, Pedersen D, et al. Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment. NOW. Int J Radiat Oncol Biol Phys. 1995;32:1531–1534
  31. Bentzen SM, Dorr W, Anscher MS, et al. Normal tissue effects: Reporting and analysis. Semin Radiat Oncol. 2003;13:189–202
  32. Vickers A. Alternative cancer cures: “Unproven” or “disproven”?. CA Cancer J Clin. 2004;54:110–118
  33. Accuray. Accuray exceeds 4,000 lung cancer patients treated with CyberKnife® system. Press release, November 16, 2007. Available from: http://www.accuray.com/PressReleases.aspx?release=720. Accessed January 15, 2008.
  34. Accuray. Clinical studies. Available from: http://www.accuray.com/Clinical-Development/Clinical-Studies.aspx. Accessed January 15, 2008.

PII: S0360-3016(08)00952-8

doi: 10.1016/j.ijrobp.2008.05.044

International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 1 , Pages 12-14 , 1 September 2008

Article Tools